Currently, there are 157.54M common shares owned by the public and among those 153.67M shares have been available to trade.
The company’s stock has a 5-day price change of -17.60% and 157.24% over the past three months. CTMX shares are trading 100.00% year to date (YTD), with the 12-month market performance up to 3.00% higher. It has a 12-month low price of $0.40 and touched a high of $2.55 over the same period. CTMX has an average intraday trading volume of 4.98 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 58.43%, 133.70%, and 106.59% respectively.
Institutional ownership of CytomX Therapeutics Inc (NASDAQ: CTMX) shares accounts for 35.35% of the company’s 157.54M shares outstanding.
It has a market capitalization of $324.54M and a beta (3y monthly) value of 1.97. The stock’s trailing 12-month PE ratio is 4.15, while the earnings-per-share (ttm) stands at $0.50. Price movements for the stock have been influenced by the stock’s volatility, which stands at 16.94% over the week and 16.82% over the month.
Earnings per share for the fiscal year are expected to decrease by -118.35%, and -538.66% over the next financial year.
Looking at the support for the CTMX, a number of firms have released research notes about the stock. H.C. Wainwright stated their Buy rating for the stock in a research note on May 15, 2025, with the firm’s price target at $5. Piper Sandler coverage for the CytomX Therapeutics Inc (CTMX) stock in a research note released on April 14, 2025 offered a Overweight rating with a price target of $2.50. Piper Sandler was of a view on May 28, 2024 that the stock is Overweight, while Wedbush gave the stock Outperform rating on May 09, 2024, issuing a price target of $8. Jefferies on their part issued Buy rating on May 06, 2024.
